← All trials
NCT04958122
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2021
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2025
- First posted
- Jul 12, 2021
- Last posted
- Jul 16, 2021
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Southern CaliforniaLead sponsor
- University of Southern CaliforniaReponsible party - principal investigator
- Cayetano Heredia UniversityCollaborator
- AIDS Healthcare FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.